# Akeso clinical trials: 157 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 157 trials with Akeso as lead sponsor, 63 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Akeso: 157 rows for $7.85, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/akeso

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 157
- Recruiting or not yet: 63
- Read on: November 19, 2026

## Trials

The 25 newest of 157, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939919 | A Study of AK158D1 in Advanced Solid Tumors | Akeso | Phase 1 | Not yet recruiting | Solid Malignant Tumor | 349 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939919) |
| October 20, 2026 | NCT07883213 | A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. | Akeso | Phase 2 | Not yet recruiting | Prurigo Nodularis (PN) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883213) |
| October 15, 2026 | NCT07875426 | A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria | Akeso | Phase 2 | Not yet recruiting | Chronic Spontaneous Urticaria | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875426) |
| September 29, 2026 | NCT07847281 | A Study of AK157D1 for Injection in Advanced Solid Tumors | Akeso | Phase 1 | Recruiting | Advanced Solid Tumors | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847281) |
| August 10, 2026 | NCT07755371 | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | Akeso | Phase 2 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755371) |
| July 14, 2026 | NCT07700979 | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of... | Akeso | Phase 3 | Recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700979) |
| June 25, 2026 | NCT07669779 | A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | Akeso | Phase 2 | Recruiting | Advanced Non Small Cell Lung Cancer (NSCLC) | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669779) |
| June 9, 2026 | NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | Akeso | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636772) |
| June 3, 2026 | NCT07623356 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer | Akeso | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623356) |
| June 1, 2026 | NCT07619001 | A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations | Akeso | Phase 1 | Not yet recruiting | Healthy Male Adults Participants | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619001) |
| May 15, 2026 | NCT07591090 | A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | Akeso | Phase 2 | Recruiting | Advanced Breast Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591090) |
| May 5, 2026 | NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | Akeso | Phase 1 | Not yet recruiting | Advanced Malignant Solid Tumors | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566247) |
| April 30, 2026 | NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | Akeso | Phase 1/2 | Not yet recruiting | Breast Cancer | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560124) |
| April 23, 2026 | NCT07547787 | A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104) | Akeso | Observational | Recruiting | Locally Advanced Unresectable or Metastatic Gastric Cancer | 610 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547787) |
| March 30, 2026 | NCT07502222 | A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis | Akeso | Phase 2 | Not yet recruiting | Moderate-to-Severe Atopic Dermatitis | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502222) |
| March 4, 2026 | NCT07449780 | A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants... | Akeso | Phase 3 | Not yet recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07449780) |
| February 27, 2026 | NCT07436234 | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis | Akeso | Phase 2 | Not yet recruiting | Seasonal Allergic Rhinitis | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436234) |
| February 27, 2026 | NCT07436221 | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma | Akeso | Phase 2 | Not yet recruiting | Asthma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436221) |
| February 17, 2026 | NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | Akeso | Phase 3 | Recruiting | Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412613) |
| January 21, 2026 | NCT07357220 | A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | Akeso | Phase 1/2 | Not yet recruiting | Colorectal Cancer With Hepatic Metastases | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357220) |
| January 14, 2026 | NCT07340476 | A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects | Akeso | Phase 1 | Active not recruiting | Healthy Male Subjects | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340476) |
| December 24, 2025 | NCT07301502 | A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease | Akeso | Phase 1 | Not yet recruiting | Alzheimer' s Disease | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301502) |
| December 15, 2025 | NCT07281326 | A Study of AK138D1 in Advanced Malignant Tumors | Akeso | Phase 1 | Recruiting | Solid Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281326) |
| December 4, 2025 | NCT07263919 | Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) | Akeso | Phase 2 | Recruiting | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263919) |
| November 24, 2025 | NCT07245446 | A Study of Ivonescimab in First-Line ES-SCLC | Akeso | Phase 2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245446) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 33 |
| Phase 1/2 | 37 |
| Phase 2 | 51 |
| Phase 3 | 35 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 60 |
| Recruiting | 39 |
| Not yet recruiting | 24 |
| Active not recruiting | 20 |
| Terminated | 8 |
| Unknown | 6 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Hepatocellular | 9 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Dermatitis, Atopic | 6 |
| Uterine Cervical Neoplasms | 5 |
| Pancreatic Neoplasms | 4 |
| Psoriasis | 4 |
| Nasopharyngeal Carcinoma | 4 |
| Ovarian Neoplasms | 3 |
| Hypercholesterolemia | 3 |
| Neoplasms | 3 |
| Hyperlipidemias | 3 |
| Neoplasm Metastasis | 2 |
| Stomach Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Asthma | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Spondylitis, Ankylosing | 2 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 2 |
| Colorectal Neoplasms | 2 |
| Skin Diseases | 2 |
| Biliary Tract Neoplasms | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Small Cell Lung Carcinoma | 2 |
| Endometrial Neoplasms | 1 |
| Colitis, Ulcerative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
- [Translation and interpreting companies in the United States](https://specstream.ai/data/businesses/translation-and-interpreting-companies/united-states)
- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
